Which has preferable valuation & earnings, APGE or MLTX?

Apogee Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apogee Therapeutics N/A N/A -$255.84M -$4.33 N/A MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.87 N/A

Is APGE or MLTX more profitable?

Apogee Therapeutics' return on equity of -32.64% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Apogee Therapeutics N/A -32.64% -31.25% MoonLake Immunotherapeutics N/A -85.15% -60.52%

Does the media refer more to APGE or MLTX?

In the previous week, Apogee Therapeutics had 4 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 12 mentions for Apogee Therapeutics and 8 mentions for MoonLake Immunotherapeutics. Apogee Therapeutics' average media sentiment score of 0.88 beat MoonLake Immunotherapeutics' score of 0.70 indicating that Apogee Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is XENE or MLTX more profitable?

Xenon Pharmaceuticals' return on equity of -49.23% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Xenon Pharmaceuticals N/A -49.23% -46.42% MoonLake Immunotherapeutics N/A -85.15% -60.52%

Does the media refer more to XENE or MLTX?

In the previous week, Xenon Pharmaceuticals and Xenon Pharmaceuticals both had 8 articles in the media. MoonLake Immunotherapeutics' average media sentiment score of 0.70 beat Xenon Pharmaceuticals' score of 0.67 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MLTX or CRSP?

In the previous week, CRISPR Therapeutics had 6 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 14 mentions for CRISPR Therapeutics and 8 mentions for MoonLake Immunotherapeutics. CRISPR Therapeutics' average media sentiment score of 0.85 beat MoonLake Immunotherapeutics' score of 0.70 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CGON or MLTX more profitable?

CG Oncology's return on equity of -23.33% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology N/A -23.33% -22.24% MoonLake Immunotherapeutics N/A -85.15% -60.52%

Does the media favor CGON or MLTX?

In the previous week, CG Oncology had 1 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 9 mentions for CG Oncology and 8 mentions for MoonLake Immunotherapeutics. CG Oncology's average media sentiment score of 0.75 beat MoonLake Immunotherapeutics' score of 0.70 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive MoonLake Immunotherapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MoonLake Immunotherapeutics (MLTX) Competitors

$18.69 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$18.64 -0.05 (-0.27%)

As of 06/12/2026 07:30 PM Eastern

Compare

MLTX vs. APGE, GRFS, XENE, CRSP, and CGON

Should you buy MoonLake Immunotherapeutics stock or one of its competitors? MarketBeat compares MoonLake Immunotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MoonLake Immunotherapeutics include Apogee Therapeutics (APGE), Grifols (GRFS), Xenon Pharmaceuticals (XENE), CRISPR Therapeutics (CRSP), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry.

How does MoonLake Immunotherapeutics compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Apogee Therapeutics currently has a consensus price target of $114.56, indicating a potential upside of 29.70%. MoonLake Immunotherapeutics has a consensus price target of $23.85, indicating a potential upside of 27.59%. Given Apogee Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Apogee Therapeutics is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38

In the previous week, Apogee Therapeutics had 4 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 12 mentions for Apogee Therapeutics and 8 mentions for MoonLake Immunotherapeutics. Apogee Therapeutics' average media sentiment score of 0.88 beat MoonLake Immunotherapeutics' score of 0.70 indicating that Apogee Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Apogee Therapeutics' return on equity of -32.64% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 24.3% of Apogee Therapeutics shares are owned by insiders. Comparatively, 12.1% of MoonLake Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Apogee Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

Apogee Therapeutics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

Summary

Apogee Therapeutics beats MoonLake Immunotherapeutics on 9 of the 14 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to Grifols?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 12.1% of MoonLake Immunotherapeutics shares are held by company insiders. Comparatively, 0.2% of Grifols shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

MoonLake Immunotherapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market. Comparatively, Grifols has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

MoonLake Immunotherapeutics presently has a consensus price target of $23.85, indicating a potential upside of 27.59%. Grifols has a consensus price target of $10.00, indicating a potential upside of 30.89%. Given Grifols' higher probable upside, analysts plainly believe Grifols is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

In the previous week, MoonLake Immunotherapeutics had 7 more articles in the media than Grifols. MarketBeat recorded 8 mentions for MoonLake Immunotherapeutics and 1 mentions for Grifols. Grifols' average media sentiment score of 1.89 beat MoonLake Immunotherapeutics' score of 0.70 indicating that Grifols is being referred to more favorably in the news media.

Company	Overall Sentiment
MoonLake Immunotherapeutics	Positive
Grifols	Very Positive

Grifols has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A
Grifols	$8.51B	0.61	$454.82M	$0.19	40.21

Grifols has a net margin of 5.54% compared to MoonLake Immunotherapeutics' net margin of 0.00%. Grifols' return on equity of 6.21% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%
Grifols	5.54%	6.21%	2.39%

Summary

Grifols beats MoonLake Immunotherapeutics on 9 of the 15 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to Xenon Pharmaceuticals?

Xenon Pharmaceuticals (NASDAQ:XENE) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Xenon Pharmaceuticals' return on equity of -49.23% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

Xenon Pharmaceuticals presently has a consensus price target of $77.20, indicating a potential upside of 48.18%. MoonLake Immunotherapeutics has a consensus price target of $23.85, indicating a potential upside of 27.59%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Xenon Pharmaceuticals is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38

95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 4.1% of Xenon Pharmaceuticals shares are owned by company insiders. Comparatively, 12.1% of MoonLake Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Xenon Pharmaceuticals has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

MoonLake Immunotherapeutics has lower revenue, but higher earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	671.53	-$345.91M	-$4.70	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

In the previous week, Xenon Pharmaceuticals and Xenon Pharmaceuticals both had 8 articles in the media. MoonLake Immunotherapeutics' average media sentiment score of 0.70 beat Xenon Pharmaceuticals' score of 0.67 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Xenon Pharmaceuticals beats MoonLake Immunotherapeutics on 8 of the 14 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to CRISPR Therapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

MoonLake Immunotherapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.74, indicating that its share price is 74% more volatile than the broader market.

MoonLake Immunotherapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%

MoonLake Immunotherapeutics presently has a consensus target price of $23.85, suggesting a potential upside of 27.59%. CRISPR Therapeutics has a consensus target price of $67.78, suggesting a potential upside of 36.10%. Given CRISPR Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CRISPR Therapeutics is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58

MoonLake Immunotherapeutics has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A
CRISPR Therapeutics	$3.51M	1,368.44	-$581.60M	-$6.22	N/A

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 12.1% of MoonLake Immunotherapeutics shares are held by company insiders. Comparatively, 4.1% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, CRISPR Therapeutics had 6 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 14 mentions for CRISPR Therapeutics and 8 mentions for MoonLake Immunotherapeutics. CRISPR Therapeutics' average media sentiment score of 0.85 beat MoonLake Immunotherapeutics' score of 0.70 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CRISPR Therapeutics beats MoonLake Immunotherapeutics on 10 of the 16 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

In the previous week, CG Oncology had 1 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 9 mentions for CG Oncology and 8 mentions for MoonLake Immunotherapeutics. CG Oncology's average media sentiment score of 0.75 beat MoonLake Immunotherapeutics' score of 0.70 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CG Oncology has higher revenue and earnings than MoonLake Immunotherapeutics. CG Oncology is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,300.30	-$160.99M	-$2.33	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

CG Oncology has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

CG Oncology presently has a consensus target price of $81.73, indicating a potential upside of 37.22%. MoonLake Immunotherapeutics has a consensus target price of $23.85, indicating a potential upside of 27.59%. Given CG Oncology's stronger consensus rating and higher possible upside, analysts plainly believe CG Oncology is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38

CG Oncology's return on equity of -23.33% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 4.8% of CG Oncology shares are held by insiders. Comparatively, 12.1% of MoonLake Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

CG Oncology beats MoonLake Immunotherapeutics on 10 of the 14 factors compared between the two stocks.

Get MoonLake Immunotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MLTX vs. The Competition

Export

Metric	MoonLake Immunotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.38B	$3.39B	$6.53B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-4.83	20.00	23.99	24.42
Price / Sales	N/A	305.33	511.38	110.47
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	4.38	8.32	10.65	6.82
Net Income	-$227.32M	$23.94M	$3.57B	$337.56M
7 Day Performance	3.83%	1.84%	0.58%	1.17%
1 Month Performance	6.50%	-0.04%	1.54%	3.16%
1 Year Performance	-57.72%	44.82%	25.40%	30.58%

MoonLake Immunotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MLTX MoonLake Immunotherapeutics	2.9846 of 5 stars	$18.69 flat	$23.85 +27.6%	-57.7%	$1.38B	N/A	N/A	2	Gap Down
APGE Apogee Therapeutics	3.2757 of 5 stars	$81.28 -2.1%	$114.56 +40.9%	+98.6%	$5.04B	N/A	N/A	91	Insider Trade
GRFS Grifols	4.7615 of 5 stars	$7.39 +0.8%	$10.00 +35.4%	-13.9%	$5.03B	$8.51B	38.87	25,247	Positive News
XENE Xenon Pharmaceuticals	3.5823 of 5 stars	$51.48 +0.5%	$77.20 +50.0%	+59.0%	$4.99B	$7.50M	N/A	210
CRSP CRISPR Therapeutics	3.51 of 5 stars	$50.60 -1.9%	$65.47 +29.4%	+20.4%	$4.91B	$3.51M	N/A	460	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MLTX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MoonLake Immunotherapeutics (MLTX) Competitors

MLTX vs. APGE, GRFS, XENE, CRSP, and CGON

How does MoonLake Immunotherapeutics compare to Apogee Therapeutics?

Summary

How does MoonLake Immunotherapeutics compare to Grifols?

Summary

How does MoonLake Immunotherapeutics compare to Xenon Pharmaceuticals?

Summary

How does MoonLake Immunotherapeutics compare to CRISPR Therapeutics?

Summary

How does MoonLake Immunotherapeutics compare to CG Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLTX vs. The Competition

MoonLake Immunotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MoonLake Immunotherapeutics (MLTX) Competitors

MLTX vs. APGE, GRFS, XENE, CRSP, and CGON

How does MoonLake Immunotherapeutics compare to Apogee Therapeutics?

Do analysts rate APGE or MLTX?

Does the media refer more to APGE or MLTX?

Is APGE or MLTX more profitable?

Do institutionals and insiders believe in APGE or MLTX?

Which has preferable valuation & earnings, APGE or MLTX?

Which has more volatility and risk, APGE or MLTX?

Summary

How does MoonLake Immunotherapeutics compare to Grifols?

Do insiders & institutionals have more ownership in MLTX or GRFS?

Which has more risk & volatility, MLTX or GRFS?

Do analysts prefer MLTX or GRFS?

Does the media favor MLTX or GRFS?

Which has higher earnings and valuation, MLTX or GRFS?

Is MLTX or GRFS more profitable?

Summary

How does MoonLake Immunotherapeutics compare to Xenon Pharmaceuticals?

Is XENE or MLTX more profitable?

Do analysts prefer XENE or MLTX?

Do insiders and institutionals believe in XENE or MLTX?

Which has more volatility & risk, XENE or MLTX?

Which has better earnings and valuation, XENE or MLTX?

Does the media refer more to XENE or MLTX?

Summary

How does MoonLake Immunotherapeutics compare to CRISPR Therapeutics?

Which has more risk & volatility, MLTX or CRSP?

Is MLTX or CRSP more profitable?

Do analysts prefer MLTX or CRSP?

Which has preferable earnings and valuation, MLTX or CRSP?

Do insiders & institutionals hold more shares of MLTX or CRSP?

Does the media prefer MLTX or CRSP?

Summary

How does MoonLake Immunotherapeutics compare to CG Oncology?

Does the media favor CGON or MLTX?

Which has stronger earnings and valuation, CGON or MLTX?

Which has more risk and volatility, CGON or MLTX?

Do analysts recommend CGON or MLTX?

Is CGON or MLTX more profitable?

Do institutionals and insiders have more ownership in CGON or MLTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLTX vs. The Competition

MoonLake Immunotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools